nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—Panic attack—Capecitabine—esophageal cancer	0.00768	0.0602	CcSEcCtD
Vilazodone—Night sweats—Capecitabine—esophageal cancer	0.0053	0.0416	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00317	0.0248	CcSEcCtD
Vilazodone—Cataract—Capecitabine—esophageal cancer	0.003	0.0236	CcSEcCtD
Vilazodone—Hyponatraemia—Cisplatin—esophageal cancer	0.00283	0.0222	CcSEcCtD
Vilazodone—Irritability—Cisplatin—esophageal cancer	0.00269	0.0211	CcSEcCtD
Vilazodone—Dry eye—Capecitabine—esophageal cancer	0.00264	0.0207	CcSEcCtD
Vilazodone—Breast disorder—Cisplatin—esophageal cancer	0.00255	0.02	CcSEcCtD
Vilazodone—Gastroenteritis—Capecitabine—esophageal cancer	0.00234	0.0184	CcSEcCtD
Vilazodone—Libido decreased—Capecitabine—esophageal cancer	0.00224	0.0176	CcSEcCtD
Vilazodone—Increased appetite—Capecitabine—esophageal cancer	0.00221	0.0173	CcSEcCtD
Vilazodone—Hyponatraemia—Capecitabine—esophageal cancer	0.00208	0.0164	CcSEcCtD
Vilazodone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00206	0.0162	CcSEcCtD
Vilazodone—Migraine—Capecitabine—esophageal cancer	0.00204	0.016	CcSEcCtD
Vilazodone—Irritability—Capecitabine—esophageal cancer	0.00198	0.0155	CcSEcCtD
Vilazodone—Connective tissue disorder—Cisplatin—esophageal cancer	0.00191	0.015	CcSEcCtD
Vilazodone—Breast disorder—Capecitabine—esophageal cancer	0.00188	0.0147	CcSEcCtD
Vilazodone—Eye disorder—Cisplatin—esophageal cancer	0.00182	0.0143	CcSEcCtD
Vilazodone—Cardiac disorder—Cisplatin—esophageal cancer	0.00181	0.0142	CcSEcCtD
Vilazodone—Malnutrition—Cisplatin—esophageal cancer	0.0017	0.0133	CcSEcCtD
Vilazodone—Flatulence—Cisplatin—esophageal cancer	0.00167	0.0131	CcSEcCtD
Vilazodone—Vision blurred—Cisplatin—esophageal cancer	0.0016	0.0125	CcSEcCtD
Vilazodone—Tremor—Cisplatin—esophageal cancer	0.00159	0.0125	CcSEcCtD
Vilazodone—Irritability—Methotrexate—esophageal cancer	0.00148	0.0116	CcSEcCtD
Vilazodone—Convulsion—Cisplatin—esophageal cancer	0.00147	0.0115	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00143	0.0113	CcSEcCtD
Vilazodone—Connective tissue disorder—Capecitabine—esophageal cancer	0.00141	0.0111	CcSEcCtD
Vilazodone—Breast disorder—Methotrexate—esophageal cancer	0.0014	0.011	CcSEcCtD
Vilazodone—Nervous system disorder—Cisplatin—esophageal cancer	0.00136	0.0107	CcSEcCtD
Vilazodone—Skin disorder—Cisplatin—esophageal cancer	0.00134	0.0105	CcSEcCtD
Vilazodone—Eye disorder—Capecitabine—esophageal cancer	0.00134	0.0105	CcSEcCtD
Vilazodone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00134	0.0105	CcSEcCtD
Vilazodone—Cardiac disorder—Capecitabine—esophageal cancer	0.00133	0.0105	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00126	0.0099	CcSEcCtD
Vilazodone—Mental disorder—Capecitabine—esophageal cancer	0.00126	0.00987	CcSEcCtD
Vilazodone—Malnutrition—Capecitabine—esophageal cancer	0.00125	0.00981	CcSEcCtD
Vilazodone—Paraesthesia—Cisplatin—esophageal cancer	0.00124	0.00975	CcSEcCtD
Vilazodone—Flatulence—Capecitabine—esophageal cancer	0.00123	0.00967	CcSEcCtD
Vilazodone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00123	0.00965	CcSEcCtD
Vilazodone—Dysgeusia—Capecitabine—esophageal cancer	0.00122	0.00961	CcSEcCtD
Vilazodone—Decreased appetite—Cisplatin—esophageal cancer	0.0012	0.00944	CcSEcCtD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.0012	0.00137	CbGpPWpGaD
Vilazodone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.0012	0.00938	CcSEcCtD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00119	0.00137	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.00119	0.00137	CbGpPWpGaD
Vilazodone—Vision blurred—Capecitabine—esophageal cancer	0.00118	0.00925	CcSEcCtD
Vilazodone—Tremor—Capecitabine—esophageal cancer	0.00117	0.00919	CcSEcCtD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00116	0.00133	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00116	0.00132	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.00115	0.00131	CbGpPWpGaD
Vilazodone—Feeling abnormal—Cisplatin—esophageal cancer	0.00114	0.00895	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00113	0.0013	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00113	0.0013	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00113	0.00129	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CA2—esophageal cancer	0.00112	0.00128	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00112	0.00128	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL2—esophageal cancer	0.00111	0.00127	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—GNG7—esophageal cancer	0.00111	0.00127	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00111	0.00127	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00111	0.00127	CbGpPWpGaD
Vilazodone—Palpitations—Capecitabine—esophageal cancer	0.0011	0.00867	CcSEcCtD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00109	0.00125	CbGpPWpGaD
Vilazodone—Arthralgia—Capecitabine—esophageal cancer	0.00106	0.00835	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—GDI2—esophageal cancer	0.00106	0.00121	CbGpPWpGaD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00106	0.00829	CcSEcCtD
Vilazodone—Dry mouth—Capecitabine—esophageal cancer	0.00104	0.00817	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—PLCE1—esophageal cancer	0.00104	0.00119	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ADH7—esophageal cancer	0.00104	0.00119	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—ANXA1—esophageal cancer	0.00103	0.00119	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.00103	0.00118	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.00102	0.00116	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00101	0.00116	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—SST—esophageal cancer	0.00101	0.00115	CbGpPWpGaD
Vilazodone—Nervous system disorder—Capecitabine—esophageal cancer	0.001	0.00785	CcSEcCtD
Vilazodone—Eye disorder—Methotrexate—esophageal cancer	0.000999	0.00784	CcSEcCtD
Vilazodone—Asthenia—Cisplatin—esophageal cancer	0.000993	0.00779	CcSEcCtD
Vilazodone—Cardiac disorder—Methotrexate—esophageal cancer	0.000992	0.00779	CcSEcCtD
Vilazodone—Skin disorder—Capecitabine—esophageal cancer	0.000991	0.00778	CcSEcCtD
Vilazodone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000986	0.00774	CcSEcCtD
Vilazodone—HTR1A—GPCR ligand binding—GHRL—esophageal cancer	0.00098	0.00112	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL2—esophageal cancer	0.000977	0.00112	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000974	0.00112	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00096	0.0011	CbGpPWpGaD
Vilazodone—Diarrhoea—Cisplatin—esophageal cancer	0.000947	0.00743	CcSEcCtD
Vilazodone—Mental disorder—Methotrexate—esophageal cancer	0.000937	0.00735	CcSEcCtD
Vilazodone—Malnutrition—Methotrexate—esophageal cancer	0.000931	0.0073	CcSEcCtD
Vilazodone—DRD2—Signaling Pathways—GDI2—esophageal cancer	0.00093	0.00107	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00093	0.00729	CcSEcCtD
Vilazodone—Insomnia—Capecitabine—esophageal cancer	0.000923	0.00724	CcSEcCtD
Vilazodone—Paraesthesia—Capecitabine—esophageal cancer	0.000916	0.00719	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000915	0.00105	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ADH1B—esophageal cancer	0.000913	0.00105	CbGpPWpGaD
Vilazodone—Dysgeusia—Methotrexate—esophageal cancer	0.000911	0.00715	CcSEcCtD
Vilazodone—DRD2—GPCR ligand binding—ANXA1—esophageal cancer	0.000908	0.00104	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—NOS2—esophageal cancer	0.000903	0.00104	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—EP300—esophageal cancer	0.000903	0.00103	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000903	0.00103	CbGpPWpGaD
Vilazodone—Dyspepsia—Capecitabine—esophageal cancer	0.000898	0.00705	CcSEcCtD
Vilazodone—Decreased appetite—Capecitabine—esophageal cancer	0.000887	0.00696	CcSEcCtD
Vilazodone—DRD2—GPCR ligand binding—SST—esophageal cancer	0.000883	0.00101	CbGpPWpGaD
Vilazodone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000881	0.00691	CcSEcCtD
Vilazodone—Vomiting—Cisplatin—esophageal cancer	0.00088	0.00691	CcSEcCtD
Vilazodone—Fatigue—Capecitabine—esophageal cancer	0.00088	0.0069	CcSEcCtD
Vilazodone—Vision blurred—Methotrexate—esophageal cancer	0.000877	0.00688	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—TYMP—esophageal cancer	0.000872	0.000999	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—GHRL—esophageal cancer	0.000861	0.000987	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP26A1—esophageal cancer	0.000848	0.000972	CbGpPWpGaD
Vilazodone—Feeling abnormal—Capecitabine—esophageal cancer	0.000841	0.0066	CcSEcCtD
Vilazodone—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.00084	0.000963	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALOX15—esophageal cancer	0.000827	0.000947	CbGpPWpGaD
Vilazodone—Nausea—Cisplatin—esophageal cancer	0.000822	0.00645	CcSEcCtD
Vilazodone—HTR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00082	0.00094	CbGpPWpGaD
Vilazodone—Convulsion—Methotrexate—esophageal cancer	0.000806	0.00633	CcSEcCtD
Vilazodone—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000799	0.000916	CbGpPWpGaD
Vilazodone—Arthralgia—Methotrexate—esophageal cancer	0.000792	0.00622	CcSEcCtD
Vilazodone—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00079	0.000905	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—TPI1—esophageal cancer	0.000789	0.000904	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTO1—esophageal cancer	0.000789	0.000904	CbGpPWpGaD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000787	0.00617	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00077	0.000883	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KMT2D—esophageal cancer	0.000766	0.000878	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALDOB—esophageal cancer	0.000756	0.000867	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.00075	0.00086	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000749	0.000858	CbGpPWpGaD
Vilazodone—Nervous system disorder—Methotrexate—esophageal cancer	0.000745	0.00584	CcSEcCtD
Vilazodone—HTR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000745	0.000854	CbGpPWpGaD
Vilazodone—Skin disorder—Methotrexate—esophageal cancer	0.000738	0.00579	CcSEcCtD
Vilazodone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000734	0.00576	CcSEcCtD
Vilazodone—Asthenia—Capecitabine—esophageal cancer	0.000732	0.00574	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—GAPDH—esophageal cancer	0.000728	0.000834	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CRABP1—esophageal cancer	0.000721	0.000827	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00072	0.000825	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.000714	0.000818	CbGpPWpGaD
Vilazodone—Diarrhoea—Capecitabine—esophageal cancer	0.000698	0.00548	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000692	0.00543	CcSEcCtD
Vilazodone—Insomnia—Methotrexate—esophageal cancer	0.000687	0.00539	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—GNG7—esophageal cancer	0.000686	0.000786	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000683	0.000783	CbGpPWpGaD
Vilazodone—Paraesthesia—Methotrexate—esophageal cancer	0.000682	0.00535	CcSEcCtD
Vilazodone—HTR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.000681	0.000781	CbGpPWpGaD
Vilazodone—Somnolence—Methotrexate—esophageal cancer	0.000675	0.0053	CcSEcCtD
Vilazodone—Dizziness—Capecitabine—esophageal cancer	0.000675	0.00529	CcSEcCtD
Vilazodone—DRD2—Signaling Pathways—KMT2D—esophageal cancer	0.000673	0.000771	CbGpPWpGaD
Vilazodone—Dyspepsia—Methotrexate—esophageal cancer	0.000669	0.00525	CcSEcCtD
Vilazodone—Decreased appetite—Methotrexate—esophageal cancer	0.00066	0.00518	CcSEcCtD
Vilazodone—DRD2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000659	0.000755	CbGpPWpGaD
Vilazodone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000656	0.00515	CcSEcCtD
Vilazodone—Fatigue—Methotrexate—esophageal cancer	0.000655	0.00514	CcSEcCtD
Vilazodone—DRD2—Signaling by GPCR—AKAP13—esophageal cancer	0.000654	0.000749	CbGpPWpGaD
Vilazodone—Vomiting—Capecitabine—esophageal cancer	0.000649	0.00509	CcSEcCtD
Vilazodone—HTR1A—Signaling by GPCR—GNG7—esophageal cancer	0.000648	0.000743	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	0.000646	0.00074	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALDH2—esophageal cancer	0.000643	0.000737	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000637	0.00073	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000629	0.00072	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000628	0.000719	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—GNG7—esophageal cancer	0.000626	0.000718	CbGpPWpGaD
Vilazodone—Feeling abnormal—Methotrexate—esophageal cancer	0.000626	0.00491	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—WWOX—esophageal cancer	0.000625	0.000716	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTT1—esophageal cancer	0.000612	0.000701	CbGpPWpGaD
Vilazodone—Nausea—Capecitabine—esophageal cancer	0.000606	0.00476	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—CYP2A6—esophageal cancer	0.000604	0.000693	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADCYAP1—esophageal cancer	0.0006	0.000687	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000598	0.000686	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PDE4D—esophageal cancer	0.000598	0.000685	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000594	0.000681	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00059	0.000676	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000584	0.00067	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—WIF1—esophageal cancer	0.000581	0.000665	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ENO1—esophageal cancer	0.000573	0.000657	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS1—esophageal cancer	0.000573	0.000657	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000571	0.000654	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—GNG7—esophageal cancer	0.000569	0.000652	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—SST—esophageal cancer	0.000569	0.000652	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PSME2—esophageal cancer	0.000565	0.000647	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PSME1—esophageal cancer	0.000565	0.000647	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000554	0.000635	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—EP300—esophageal cancer	0.000552	0.000633	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000552	0.000633	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—WWOX—esophageal cancer	0.000548	0.000628	CbGpPWpGaD
Vilazodone—Asthenia—Methotrexate—esophageal cancer	0.000545	0.00428	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000536	0.000614	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000531	0.000608	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FKBP1A—esophageal cancer	0.000522	0.000598	CbGpPWpGaD
Vilazodone—Diarrhoea—Methotrexate—esophageal cancer	0.00052	0.00408	CcSEcCtD
Vilazodone—HTR1A—Signaling by GPCR—SST—esophageal cancer	0.000516	0.000592	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000513	0.000588	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—WIF1—esophageal cancer	0.00051	0.000584	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—GHRL—esophageal cancer	0.000503	0.000577	CbGpPWpGaD
Vilazodone—Dizziness—Methotrexate—esophageal cancer	0.000502	0.00394	CcSEcCtD
Vilazodone—DRD2—Signaling by GPCR—CXCL2—esophageal cancer	0.000501	0.000574	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PFN1—esophageal cancer	0.000501	0.000574	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—SST—esophageal cancer	0.000499	0.000572	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000492	0.000564	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000492	0.000564	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP1B1—esophageal cancer	0.000487	0.000558	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—GHRL—esophageal cancer	0.000486	0.000557	CbGpPWpGaD
Vilazodone—Vomiting—Methotrexate—esophageal cancer	0.000483	0.00379	CcSEcCtD
Vilazodone—DRD2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00047	0.000539	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ANXA1—esophageal cancer	0.000466	0.000534	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP19A1—esophageal cancer	0.000458	0.000525	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—SST—esophageal cancer	0.000453	0.00052	CbGpPWpGaD
Vilazodone—Nausea—Methotrexate—esophageal cancer	0.000451	0.00354	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—ELMO1—esophageal cancer	0.00045	0.000516	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—GHRL—esophageal cancer	0.000442	0.000506	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PFN1—esophageal cancer	0.00044	0.000504	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKAP13—esophageal cancer	0.00044	0.000504	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CA1—esophageal cancer	0.000418	0.000479	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000418	0.000479	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—HMOX1—esophageal cancer	0.000418	0.000479	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000406	0.000465	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000402	0.000461	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ABCB1—esophageal cancer	0.000401	0.00046	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ELMO1—esophageal cancer	0.000395	0.000453	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TP53—esophageal cancer	0.000395	0.000453	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKAP13—esophageal cancer	0.000386	0.000443	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GNG7—esophageal cancer	0.000383	0.000439	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CA2—esophageal cancer	0.000383	0.000438	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—XIAP—esophageal cancer	0.000359	0.000411	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000357	0.000409	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000356	0.000408	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000356	0.000408	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PDE4D—esophageal cancer	0.000353	0.000405	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000339	0.000389	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	0.000337	0.000386	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GNG7—esophageal cancer	0.000336	0.000385	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000322	0.000369	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000322	0.000369	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PSME2—esophageal cancer	0.000315	0.000361	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PSME1—esophageal cancer	0.000315	0.000361	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—XIAP—esophageal cancer	0.000315	0.000361	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000314	0.000359	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000312	0.000357	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SST—esophageal cancer	0.000305	0.00035	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000298	0.000342	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	0.000298	0.000341	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000297	0.000341	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GHRL—esophageal cancer	0.000297	0.000341	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL2—esophageal cancer	0.000296	0.000339	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000292	0.000335	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.00029	0.000332	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000283	0.000324	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSME2—esophageal cancer	0.000277	0.000317	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSME1—esophageal cancer	0.000277	0.000317	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ANXA1—esophageal cancer	0.000275	0.000315	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000273	0.000313	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA1—esophageal cancer	0.000273	0.000313	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.00027	0.000309	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TPI1—esophageal cancer	0.00027	0.000309	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CREBBP—esophageal cancer	0.000268	0.000307	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SST—esophageal cancer	0.000268	0.000307	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000267	0.000306	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GHRL—esophageal cancer	0.000261	0.000299	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	0.000261	0.000299	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000258	0.000296	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FBXW7—esophageal cancer	0.000257	0.000294	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA2—esophageal cancer	0.00025	0.000287	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000249	0.000285	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000246	0.000282	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NOS3—esophageal cancer	0.00024	0.000275	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000236	0.000271	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000234	0.000269	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	0.000234	0.000268	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000232	0.000266	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000232	0.000266	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	0.000224	0.000257	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.00022	0.000252	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—esophageal cancer	0.00022	0.000252	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000209	0.000239	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	0.000208	0.000238	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000207	0.000237	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000204	0.000234	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SMAD4—esophageal cancer	0.000197	0.000225	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000196	0.000224	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000196	0.000224	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000195	0.000223	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000193	0.000221	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000193	0.000221	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.00019	0.000217	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000185	0.000212	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	0.000183	0.00021	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—EP300—esophageal cancer	0.000183	0.000209	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000176	0.000202	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000176	0.000202	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—esophageal cancer	0.000175	0.000201	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000169	0.000194	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000166	0.000191	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	0.000165	0.000189	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000163	0.000186	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000161	0.000185	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—esophageal cancer	0.000161	0.000184	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000157	0.000179	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—esophageal cancer	0.000154	0.000176	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000153	0.000176	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	0.00015	0.000171	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	0.000147	0.000168	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	0.000145	0.000166	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000144	0.000165	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000143	0.000164	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000141	0.000161	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.000137	0.000157	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—esophageal cancer	0.000137	0.000157	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—esophageal cancer	0.000135	0.000155	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	0.000135	0.000155	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—esophageal cancer	0.000134	0.000154	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CREBBP—esophageal cancer	0.000131	0.000151	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—esophageal cancer	0.000129	0.000148	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS1—esophageal cancer	0.000128	0.000147	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO1—esophageal cancer	0.000128	0.000147	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	0.000128	0.000146	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSME2—esophageal cancer	0.000126	0.000145	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSME1—esophageal cancer	0.000126	0.000145	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	0.000125	0.000144	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000123	0.000141	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—esophageal cancer	0.000118	0.000135	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000112	0.000128	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—esophageal cancer	0.000111	0.000127	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—esophageal cancer	0.00011	0.000126	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	0.000109	0.000125	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	0.000107	0.000123	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	0.000102	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EP300—esophageal cancer	0.000102	0.000117	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—esophageal cancer	9.72e-05	0.000111	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	9.4e-05	0.000108	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMOX1—esophageal cancer	9.34e-05	0.000107	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.16e-05	0.000105	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.96e-05	0.000103	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EP300—esophageal cancer	8.95e-05	0.000103	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—esophageal cancer	8.88e-05	0.000102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—esophageal cancer	8.68e-05	9.95e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—esophageal cancer	8.2e-05	9.4e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—esophageal cancer	7.8e-05	8.93e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—esophageal cancer	7.63e-05	8.74e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	7.54e-05	8.64e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.5e-05	8.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—esophageal cancer	7.29e-05	8.36e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	6.62e-05	7.58e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—esophageal cancer	6.4e-05	7.34e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—EP300—esophageal cancer	6.24e-05	7.15e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.99e-05	6.87e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—esophageal cancer	5.36e-05	6.15e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.91e-05	5.62e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.62e-05	5.29e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—EP300—esophageal cancer	4.08e-05	4.68e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.02e-05	3.46e-05	CbGpPWpGaD
